IGS1 Stock Chart & Stats
€0.26
€0.00(0.00%)
At close: 4:00 PM EDT
€0.26
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.21 - €0.36
Previous CloseN/A
Volume0.00
Average Volume (3M)540.00
Market Cap
€25.50M
Enterprise Value€26.51M
Total Cash (Recent Filing)€354.00K
Total Debt (Recent Filing)€1.08M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Nov 18, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding116,142,320
10 Day Avg. Volume403
30 Day Avg. Volume540
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.34Price Target Upside1954.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€979.38K
Bulls Say, Bears Say
Bulls Say
Modest LeverageModest leverage gives IGC more financial flexibility than a highly indebted peer, reducing immediate balance-sheet pressure. This can help preserve capacity to fund clinical development and manage obligations while the company works toward regulatory progress and potential commercialization.
Financing AccessDebt conversion reduces liabilities while the extended loan facility preserves access to financing, supporting continued development activity. Although funding needs remain substantial, these actions improve near-term capital availability and provide flexibility to advance the pipeline.
Positive Gross MarginA positive gross margin indicates that the company retains some economic contribution from its current revenue base, even though revenue is small. If revenue expands through successful development and commercialization, this contribution could support operating leverage over time.
Bears Say
Small, Declining RevenueVery small and declining revenue leaves IGC with limited internal funding for clinical development and operating expenses. Until a candidate reaches approval or a meaningful licensing arrangement is achieved, the business has not established a durable commercial revenue engine.
Severe UnprofitabilityLosses remain exceptionally large relative to revenue, showing that the current cost structure is far from breakeven. Persistent unprofitability can consume shareholder capital, constrain strategic flexibility, and require additional financing before the pipeline can generate product revenue.
Persistent Cash BurnNegative operating and free cash flow means IGC cannot currently fund its activities from internally generated cash. Continued burn increases reliance on debt, equity, or strategic transactions and could pressure the company’s ability to sustain development without further capital.
IGC Pharma News
IGS1 FAQ
What was IGC Pharma’s price range in the past 12 months?
IGC Pharma lowest stock price was €0.21 and its highest was €0.36 in the past 12 months.
What is IGC Pharma’s market cap?
IGC Pharma’s market cap is €25.50M.
When is IGC Pharma’s upcoming earnings report date?
IGC Pharma’s upcoming earnings report date is Nov 18, 2026 which is in 25 days.
How were IGC Pharma’s earnings last quarter?
IGC Pharma released its earnings results on Jun 15, 2026. The company reported -€0.018 earnings per share for the quarter.
Is IGC Pharma overvalued?
According to Wall Street analysts IGC Pharma’s price is currently Undervalued.
Does IGC Pharma pay dividends?
IGC Pharma does not currently pay dividends.
What is IGC Pharma’s EPS estimate?
IGC Pharma’s EPS estimate is -0.02.
How many shares outstanding does IGC Pharma have?
IGC Pharma has 116,142,320 shares outstanding.
What happened to IGC Pharma’s price movement after its last earnings report?
IGC Pharma reported an EPS of -€0.018 in its last earnings report. Following the earnings report the stock price went up 2.479%.
Which hedge fund is a major shareholder of IGC Pharma?
Currently, no hedge funds are holding shares in DE:IGS1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IGC Pharma
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
IGS1 Stock 12 Month Forecast
Average Price Target
€5.34
▲(1954.65% Upside)